MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 406261 | Name: PFI-1
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PFI-1 is a potent and highly selective protein interaction Inhibitor, which targets BET bromodomain. PFI-1 that efficiently blocks the interaction of BET BRDs with acetylated histone tails. Co-crystal structures showed that PFI-1 acts as an acetyl-lysine (Kac) mimetic inhibitor efficiently occupying the Kac binding site in BRD4 and BRD2. PFI-1 has antiproliferative effects on leukaemic cell lines and efficiently abrogates their clonogenic growth. Exposure of sensitive cell lines with PFI-1 results in G1 cell cycle arrest, down-regulation of MYC expression as well as induction of apoptosis and induces differentiation of primary leukaemic blasts.

Chemical Structure

PFI-1
PFI-1
CAS#1403764-72-6

Theoretical Analysis

MedKoo Cat#: 406261

Name: PFI-1

CAS#: 1403764-72-6

Chemical Formula: C16H17N3O4S

Exact Mass: 347.0940

Molecular Weight: 347.39

Elemental Analysis: C, 55.32; H, 4.93; N, 12.10; O, 18.42; S, 9.23

Price and Availability

Size Price Availability Quantity
25mg USD 250.00 2 Weeks
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,650.00 2 Weeks
1g USD 3,250.00 2 Weeks
2g USD 5,850.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PFI1; PFI 1; PFI-1
IUPAC/Chemical Name
2-methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide
InChi Key
TXZPMHLMPKIUGK-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H17N3O4S/c1-19-10-11-9-12(7-8-13(11)17-16(19)20)18-24(21,22)15-6-4-3-5-14(15)23-2/h3-9,18H,10H2,1-2H3,(H,17,20)
SMILES Code
O=S(C1=CC=CC=C1OC)(NC2=CC3=C(NC(N(C)C3)=O)C=C2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot# A21M12B10
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
PFI-1 is a selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC50 of 0.22 μM in a cell-free assay.
In vitro activity:
PFI-1 has antiproliferative effects on leukemic cell lines and efficiently abrogates their clonogenic growth. Exposure of sensitive cell lines with PFI-1 results in G1 cell-cycle arrest, downregulation of MYC expression, as well as induction of apoptosis and induces differentiation of primary leukemic blasts. Intriguingly, cells exposed to PFI-1 showed significant downregulation of Aurora B kinase, thus attenuating phosphorylation of the Aurora substrate H3S10, providing an alternative strategy for the specific inhibition of this well-established oncology target. Reference: Cancer Res. 2013 Jun 1;73(11):3336-46. https://pubmed.ncbi.nlm.nih.gov/23576556/
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMF 12.0 34.54
DMSO 32.9 94.78
DMSO:PBS (pH 7.2) (1:1) 0.5 1.44
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 347.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, Fedorov O, Brennan P, Bunnage ME, Owen DR, Bradner JE, Taniere P, O'Sullivan B, Müller S, Schwaller J, Stankovic T, Knapp S. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res. 2013 Jun 1;73(11):3336-46. doi: 10.1158/0008-5472.CAN-12-3292. Epub 2013 Apr 10. PMID: 23576556; PMCID: PMC3673830. 2. Fish PV, Filippakopoulos P, Bish G, Brennan PE, Bunnage ME, Cook AS, Federov O, Gerstenberger BS, Jones H, Knapp S, Marsden B, Nocka K, Owen DR, Philpott M, Picaud S, Primiano MJ, Ralph MJ, Sciammetta N, Trzupek JD. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem. 2012 Nov 26;55(22):9831-7. doi: 10.1021/jm3010515. Epub 2012 Nov 8. PMID: 23095041; PMCID: PMC3506127.
In vitro protocol:
1. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, Fedorov O, Brennan P, Bunnage ME, Owen DR, Bradner JE, Taniere P, O'Sullivan B, Müller S, Schwaller J, Stankovic T, Knapp S. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res. 2013 Jun 1;73(11):3336-46. doi: 10.1158/0008-5472.CAN-12-3292. Epub 2013 Apr 10. PMID: 23576556; PMCID: PMC3673830. 2. Fish PV, Filippakopoulos P, Bish G, Brennan PE, Bunnage ME, Cook AS, Federov O, Gerstenberger BS, Jones H, Knapp S, Marsden B, Nocka K, Owen DR, Philpott M, Picaud S, Primiano MJ, Ralph MJ, Sciammetta N, Trzupek JD. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem. 2012 Nov 26;55(22):9831-7. doi: 10.1021/jm3010515. Epub 2012 Nov 8. PMID: 23095041; PMCID: PMC3506127.
In vivo protocol:
TBD
1: Vasiliadis AV, Troupis T, Chrysikos D, Chytas D, Noussios G. Trochlea Dysplasia as the Major Anatomic Risk Factors for Patellofemoral Joint Instability: An Infographic as a Visual Learning Tool. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2024 Jul 15;45(2):67-70. doi: 10.2478/prilozi-2024-0017. PMID: 39008645. 2: Bai M, Huang Y, Suo X, Wang L, Han W, Zhang W. BET bromodomain inhibitors PFI-1 and CPI-203 suppress the development of follicular lymphoma via regulating Wnt/β-catenin signaling. Heliyon. 2024 Feb 27;10(5):e27149. doi: 10.1016/j.heliyon.2024.e27149. PMID: 38463851; PMCID: PMC10920712. 3: Situ Y, Liang Q, Zeng Z, Chen J, Shao Z, Xu Q, Lu X, Cui Y, Zhang J, Lu L, Deng L. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets. Front Endocrinol (Lausanne). 2023 Jan 30;14:1089531. doi: 10.3389/fendo.2023.1089531. PMID: 36793283; PMCID: PMC9922706. 4: Jeon D, Kim N, Um SJ. BET Inhibitors Induce p53-Independent Growth Arrest in HCT116 Cells via Epigenetic Control of the E2F1/c-MYC Axis. Biol Pharm Bull. 2023;46(1):12-18. doi: 10.1248/bpb.b22-00343. PMID: 36596519. 5: Wang Q, Pan Y, Luo H, Zhang Y, Gao F, Wang J, Zheng J. Novel Approaches for the Solid-Phase Synthesis of Dihydroquinazoline-2(1H)-One Derivatives and Biological Evaluation as Potential Anticancer Agents. Molecules. 2022 Dec 5;27(23):8577. doi: 10.3390/molecules27238577. PMID: 36500678; PMCID: PMC9737648. 6: Tsai HW, Li CJ, Lin LT, Chiang AJ, Chen SN, Wen ZH, Tsui KH. Expression status and prognostic significance of mitochondrial dynamics OPA3 in human ovarian cancer. Aging (Albany NY). 2022 May 4;14(9):3874-3886. doi: 10.18632/aging.204050. Epub 2022 May 4. PMID: 35507809; PMCID: PMC9134952. 7: Zeng S, Qiu Q, Zhou Y, Xiao Y, Wang J, Li R, Xu S, Shi M, Wang C, Kuang Y, Lao M, Cai X, Liang L, Xu H. The suppression of Brd4 inhibits peripheral plasma cell differentiation and exhibits therapeutic potential for systemic lupus erythematosus. Int Immunopharmacol. 2022 Feb;103:108498. doi: 10.1016/j.intimp.2021.108498. Epub 2021 Dec 28. PMID: 34972067. 8: Zhang H, Bai F, Song H, Yang J, Wang X, Ye Q, Zhou Y. Cumulative effect of risk and protective factors on unintentional injury for Chinese rural children: a nested case-control study. BMC Public Health. 2021 Sep 23;21(1):1730. doi: 10.1186/s12889-021-11769-7. PMID: 34556060; PMCID: PMC8461983. 9: Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Colombo N, Fernandez C, Alfaro V, Kahatt C, Nieto A, Zeaiter A, Aracil M, Vidal L, Pardo- Burdalo B, Papai Z, Kristeleit R, O'Malley DM, Benjamin I, Pautier P, Lorusso D. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021 Nov;163(2):237-245. doi: 10.1016/j.ygyno.2021.08.032. Epub 2021 Sep 11. PMID: 34521554. 10: Quezada E, Cappelli C, Diaz I, Jury N, Wightman N, Brown RH Jr, Montecino M, van Zundert B. BET bromodomain inhibitors PFI-1 and JQ1 are identified in an epigenetic compound screen to enhance C9ORF72 gene expression and shown to ameliorate C9ORF72-associated pathological and behavioral abnormalities in a C9ALS/FTD model. Clin Epigenetics. 2021 Mar 16;13(1):56. doi: 10.1186/s13148-021-01039-z. PMID: 33726839; PMCID: PMC7962347. 11: Altenburg B, Frings M, Schöbel JH, Goßen J, Pannen K, Vanderliek K, Rossetti G, Koschmieder S, Chatain N, Bolm C. Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies. ACS Med Chem Lett. 2020 Apr 2;11(10):1928-1934. doi: 10.1021/acsmedchemlett.9b00625. PMID: 33062175; PMCID: PMC7549261. 12: Tenhunen J, Kokkola T, Huovinen M, Rahnasto-Rilla M, Lahtela-Kakkonen M. Impact of structurally diverse BET inhibitors on SIRT1. Gene. 2020 May 30;741:144558. doi: 10.1016/j.gene.2020.144558. Epub 2020 Mar 10. PMID: 32165310. 13: Lines KE, Filippakopoulos P, Stevenson M, Müller S, Lockstone HE, Wright B, Knapp S, Buck D, Bountra C, Thakker RV. Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells. Endocr Relat Cancer. 2020 Mar;27(3):163-174. doi: 10.1530/ERC-19-0448. PMID: 31935194; PMCID: PMC7040567. 14: Thijssen M, Janssen L, le Noble J, Foudraine N. Facing SpO2 and SaO2 discrepancies in ICU patients: is the perfusion index helpful? J Clin Monit Comput. 2020 Aug;34(4):693-698. doi: 10.1007/s10877-019-00371-3. Epub 2019 Aug 7. PMID: 31392655; PMCID: PMC7366881. 15: Zhang Z, Gu L, Wang B, Huang W, Zhang Y, Ma Z, Zeng S, Shen Z. Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping. J Enzyme Inhib Med Chem. 2019 Dec;34(1):808-817. doi: 10.1080/14756366.2019.1587417. PMID: 30879350; PMCID: PMC6427567. 16: Hupe MC, Hoda MR, Zengerling F, Perner S, Merseburger AS, Cronauer MV. The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells. World J Urol. 2019 Feb;37(2):343-349. doi: 10.1007/s00345-018-2382-8. Epub 2018 Jun 22. PMID: 29934670. 17: Dong J, Xu H, Jin G, Xin D, Zhang J, Kang K, Gao S, Chen B, Shen Y. The adaptive change of patellofemoral joint after arthroscopic discoid lateral meniscus plasty: An observational study. Medicine (Baltimore). 2018 Feb;97(6):e9827. doi: 10.1097/MD.0000000000009827. PMID: 29419685; PMCID: PMC5944665. 18: Lu P, Shen Y, Yang H, Wang Y, Jiang Z, Yang X, Zhong Y, Pan H, Xu J, Lu H, Zhu H. BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency. Sci Rep. 2017 Nov 30;7(1):16646. doi: 10.1038/s41598-017-16816-1. PMID: 29192216; PMCID: PMC5709369. 19: Valinciute G, Weigel C, Veldwijk MR, Oakes CC, Herskind C, Wenz F, Plass C, Schmezer P, Popanda O. BET-bromodomain inhibitors modulate epigenetic patterns at the diacylglycerol kinase alpha enhancer associated with radiation-induced fibrosis. Radiother Oncol. 2017 Oct;125(1):168-174. doi: 10.1016/j.radonc.2017.08.028. Epub 2017 Sep 12. PMID: 28916223. 20: Evanno E, Godet J, Piccirilli N, Guilhot J, Milin S, Gombert JM, Fouchaq B, Roche J. Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to- mesenchymal transition in lung cancer. Clin Epigenetics. 2017 Aug 8;9:80. doi: 10.1186/s13148-017-0380-0. PMID: 28804523; PMCID: PMC5549304.